Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Press Announcements

Press Announcements Home
          News & Events
          FDA Newsroom
          Press Announcements
          FDA Roundup: October 3, 2023Press Announcements FDA News Release
  FDA Roundup: October 3, 2023

  
  Share
    Post
    Linkedin

    Email
    PrintFor Immediate Release:
                  October 03, 2023
 

  
      
       

  Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:

Today, the FDA, in partnership with the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), announced the public workshop “Defining ‘Candy-Like’ Nonprescription Drug Products.” The workshop will bring together stakeholders from the FDA, academia and industry to discuss available research on this topic, aid in the development of approaches for outlining appropriate dosage forms and consider patient-focused outreach to better understand how candy-like characteristics are viewed by consumers. The workshop will be held on Monday, October 30 from 8:30 a.m. to 4 p.m. ET both on-site at the FDA’s White Oak Campus (Silver Spring, MD) and virtually. All attendees must register.
	On Monday, the FDA issued minor updates to the final guidance: Electronic Submissions Template for Medical Devices 510(k) Submissions. The updates are to support the use of the Electronic Submission Template and Resource (eSTAR) through the CDRH Portal. As of October 1, 2023, all 510(k) submissions, unless exempted, must be submitted as electronic submissions using eSTAR. Use of eSTAR for all 510(k) submissions is part of the FDA’s ongoing efforts to modernize the 510(k) Program, and implement MDUFA V and 745A(b) of the Federal Food, Drug, and Cosmetic Act. 
	eSTAR is intended to enhance the incoming quality of submissions for a wide range of medical devices by helping to ensure submitters provide quality, comprehensive data for premarket review. With a standardized format, submitters can ensure their submissions are complete, and the FDA can conduct premarket reviews more efficiently to help promote timely access to safe, effective, and high-quality medical devices.
	On Friday, the FDA approved Rivfloza (Novo Nordisk Inc.), indicated to lower urinary oxalate (a substance consumed in food and produced by the body) levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1), a rare genetic disorder that can cause damage to the kidneys and other organs. The most common adverse reactions were injection site reactions. View the full prescribing information for Rivfloza.
	On Friday, the FDA approved Tofidence (tocilizumab-bavi), the first biosimilar product to Actemra (tocilizumab), to treat rheumatoid arthritis in adults, polyarticular juvenile arthritis in ages 2 and older, and systemic juvenile idiopathic arthritis in ages 2 and older. The most common side effects associated with tocilizumab products are upper respiratory tract infections, nasopharyngitis (common cold), headache, hypertension, increased ALT (elevated liver enzymes), and injection site reactions. Please see the full prescribing information for additional information on risks associated with Tofidence. The FDA granted this approval to Biogen MA Inc.
	On Friday, the FDA granted marketing authorization to the Procise IFX and Procise ADL assays, two in vitro diagnostic tests intended to measure levels of infliximab and adalimumab, respectively, medications used to treat patients with Crohn's disease and ulcerative colitis. Commonly referred to as inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis affect more than three million patients in the U.S., according to the CDC. Many of these patients experience moderate to severe symptoms that require lifelong therapy to induce remission and prevent relapse. These marketing authorizations are the latest examples of the FDA’s ongoing commitment to advance access to safe and effective diagnostic testing intended to aid healthcare professionals in making more informed clinical management decisions for patients.Related Information
  
  Related Information
              FDA Newsroom

###
  Boilerplate
      The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Inquiries
  
    
        
         Media:
                 
      
                            FDA Office of Media Affairs
           
           
                      888-INFO-FDA
    Consumer:
                        888-INFO-FDA

                                                                                  Content current as of:
      10/03/2023
               
               
Regulated Product(s)
		 Biologics
			  			     			  			     Drugs
			     			  			     Medical Devices   

        Follow FDA
            Follow @US_FDAon X
                Follow FDAon Facebook
                Follow @FDAMediaon XMore Press Announcements
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop